AirSculpt Technologies (NASDAQ:AIRS) Reports Disappointing Q3 Earnings Amidst Operational Headwinds

• AirSculpt Technologies (NASDAQ:AIRS) reported a wider-than-expected third-quarter loss of $0.10 per share and missed revenue estimates with $31.9 million.
• The company cited weaker marketing returns, operational issues at clinics, and the negative impact of Google (NASDAQ: GOOGL)’s AI Overviews on patient acquisition.
• AirSculpt lowered its full-year financial outlook but is actively addressing challenges and expanding into procedures related to GLP-1 weight-loss drugs, while also refinancing its term loan.

AirSculpt Technologies (NASDAQ:AIRS), a leading provider of body-contouring procedures, announced its third-quarter 2026 financial results before market open on November 6, 2026. The company reported a significant Q3 loss of $0.10 per share, which was wider than the estimated loss of $0.03 per share. Furthermore, Q3 revenue came in at $31.9 million, falling short of the analyst estimate of $34.3 million.

This Q3 performance reflects a substantial decline in financial health, with revenue falling 8.7% from $35.0 million reported in the same period last year. Adjusted EBITDA, a key measure of operating profit, plummeted to approximately $400,000 from $3 million. This sharp drop in Adjusted EBITDA highlights that the weaker sales directly led to a more pronounced decrease in profitability for AirSculpt.

CEO Yogi Jashnani expressed disappointment with the Q3 results, attributing the underperformance to several factors, including weaker returns from marketing investments and operational challenges at various AirSculpt clinics, as noted by MarketBeat. Jashnani also highlighted that Google (NASDAQ: GOOGL)’s AI Overviews feature negatively impacted patient acquisition, reducing the number of potential clients reaching AirSculpt’s official website.

In response to these ongoing challenges, AirSculpt has revised and lowered its full-year revenue and profit outlook. The updated forecast anticipates that the third-quarter operational difficulties will persist into the fourth quarter. Despite the setbacks, Jashnani affirmed that AirSculpt is actively addressing the root causes of the weaker financial performance and reported promising progress in expanding its range of procedures related to GLP-1 weight-loss drugs, a growing market segment.

From a valuation perspective, AirSculpt currently holds a trailing price-to-earnings (P/E) ratio of approximately -4.06, indicative of its negative earnings. The company's current ratio stands at 0.85, signaling that its current assets are less than its current liabilities, which could raise liquidity concerns. Post-quarter, AirSculpt successfully refinanced its term loan, extending the debt’s maturity to 2031, a move that provides some financial flexibility.